Melbourne, Australia;
11 June 2021 – Key Chinese Patent covering OBM-1701 Granted
Oculus Biomed Limited (“OBM”) is pleased to announce the grant of the Chinese Patent which covers the OBM-1701, OBM’s leading novel drug candidate for treating wet-type age-related macular degeneration (wet-AMD), and its related analogues. The term of the Chinese patent extend its patent protection to April 2036. Corresponding patent applications have already been granted in 7 other countries, including Australia, New Zealand, USA, Canada, Japan, South Korea, and Taiwan(R.O.C.). It is also allowed by The European Patent Office on 2nd June 2021. Applications are currently pending in Malaysia and Singapore, Hong Kong and Macau.
